Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-168 in Relapsed or Refractory B-Cell Lymphoma
NCT04993690Phase 1Recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-10561 in B cell lymphoma (6 arms), sponsored by Lupeng Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 24 Months, Recommended dose for Phase 2 at 24 Months and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
HS-10561
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04993690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993690.